Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Repetitive Transcranial Magnetic Stimulation for Dementia

Start: January 2016
End: October 2024
Enrollment: 62

What Is This Study About?

This clinical trial will test whether repetitive transcranial magnetic stimulation (rTMS) improves cognitive function in people mild to moderate cognitive impairment or dementia and whether responses to the intervention are correlated with the initial severity of cognitive impairment.

Do I Qualify To Participate in This Study?

Minimum Age: 55 Years

Maximum Age: 99 Years

Must have:

  • Diagnosed with mild cognitive impairment or dementia likely due to Alzheimer's disease
  • Ability to obtain a motor threshold, determined during the screening process
  • Stable condition and living environment to enable attendance at scheduled clinic visits
  • If taking prescription medication for cognition, on a stable dose for at least 4 weeks prior to joining the study; willing to remain on stable regimen during the treatment phase
  • Able to read, verbalize understanding, and voluntarily sign the informed consent form to be signed by participant or legal representative

Must NOT have:

  • Prior exposure to rTMS or electroconvulsive therapy
  • Unable to safely withdraw from medications that substantially increase the risk of having seizures at least 2 weeks prior to starting treatment
  • Cardiac pacemaker, cochlear implant, or other implanted device or metal in the brain
  • Current substance abuse
  • Active current suicidal intent or plan
  • Current or prior history of seizure disorder
  • Traumatic brain injury within the last 2 months
  • Participation in interventional clinical trial at the same time as this trial
  • Known current psychosis
  • Current or prior history of mass lesion, cerebral infarct, or other non-cogitative, active central nervous system disease that would increase the risk for seizure
  • Not fluent in English or hearing impairment severe enough to impair comprehension

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: VA Office of Research and Development

Source: ClinicalTrials.gov ID: NCT02621424

 

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health